Keep magnesium blends uniform from the blender to the finished unit

Define the variation you need to control

Start with a process map: dispensing, any preblend, main blending, discharge, transfer, intermediate storage, hopper feeding and unit formation. Mark changes in container, drop height, hold time and equipment speed. The question is whether a consumer unit receives the intended composition after all these steps.

Particle differences deserve attention. Original experimental work found that particle size differences affected blend uniformity, while a separate die-filling study demonstrated segregation in model pharmaceutical mixtures. These findings support checking the actual process; they do not establish a magnesium-specific acceptance limit [1] [2].

Record the magnesium ingredient lot, particle-size information, bulk density, moisture basis and the corresponding properties of major blend components. Then decide which differences warrant a controlled trial rather than assuming every material with the same elemental assay behaves identically.

Use a staged trial instead of one composite result

The following is a development framework, not a prescribed sampling count or release standard. The quality team should choose sample locations, quantities, analytical methods and acceptance criteria before the run.

Keep individual results visible before calculating a mean. A single combined sample answers a different question from the distribution of individual units. Reconcile any unexpected result with sample location, collection technique, preparation and instrument records before deciding whether the problem is mixing or measurement.

On smaller screens, scroll the table horizontally.

Read concentration and unit weight together

In an illustrative trial, two 500 mg fills each contain 10% elemental magnesium by mass, so each supplies 50 mg magnesium. If one fill remains 500 mg but its concentration falls to 9%, its magnesium content becomes 45 mg. If concentration stays at 10% while fill weight falls to 450 mg, the result is also 45 mg. The corrective actions differ: one concerns composition distribution, the other unit filling.

Plot assay against production sequence and compare it with fill weight and process events. A gradual trend after a hopper refill deserves a different investigation from scattered analytical replicates. Do not respond to every low result by adding extra magnesium to the entire formulation.

Turn the trial into controls that a CMO can repeat

Retain the successful component lots, addition sequence, equipment configuration, loading range, blend conditions, transfer route and hold conditions. Challenge a realistic change, such as a different approved ingredient lot or a planned production interruption, before treating the trial as transferable.

For U.S. dietary supplements, component, in-process and finished-product specifications form part of the manufacturing control framework. The manufacturer must document why the selected in-process controls help support finished-product specifications [3].

Bring the process map and observed variation to your ingredient supplier and CMO. A useful technical discussion starts with where variation appeared and what changed between stages.

Common questions